BRAF and melanoma: Immunoblotting with phospho-specific antibodies confirmed these results in all BRAFV600E melanoma cells treated with either PLX4032 (Fig. 2B) or GSK2118436 (Fig. S3C) and lack of effect in WT BRAF MeWo cells (Fig. S3B).